data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Turning Point
(NASDAQ:TPTX)
$75.11
-0.14[-0.19%]
At close: Jul 1
$75.11
00
After Hours: 4:04PM EDT
Day High/Low74.93 - 75.3
52 Week High/Low23.77 - 82.2
Open / Close75.21 / 75.11
Float / Outstanding47.2M / 49.7M
Vol / Avg.2.2M / 1.7M
Mkt Cap3.7B
P/E-
50d Avg. Price48.59
Div / Yield-
Payout Ratio-
EPS-1.5
Total Float47.2M

Turning Point (NASDAQ:TPTX), Quotes and News Summary

Turning Point (NASDAQ: TPTX)

Day High/Low74.93 - 75.3
52 Week High/Low23.77 - 82.2
Open / Close75.21 / 75.11
Float / Outstanding47.2M / 49.7M
Vol / Avg.2.2M / 1.7M
Mkt Cap3.7B
P/E-
50d Avg. Price48.59
Div / Yield-
Payout Ratio-
EPS-1.5
Total Float47.2M
Benzinga - Jun 24, 2022, 9:02AM
Benzinga - Jun 13, 2022, 8:07AM
Benzinga - Jun 6, 2022, 11:09AM
Benzinga - Jun 6, 2022, 6:38AM
Benzinga - Jun 6, 2022, 6:21AM
Benzinga - Jun 3, 2022, 10:03AM
Benzinga - Jun 3, 2022, 8:52AM
Benzinga - Jun 3, 2022, 7:01AM
Benzinga - May 24, 2022, 10:09AM
Benzinga - May 20, 2022, 7:35AM
Benzinga - May 11, 2022, 4:56AM
Benzinga - May 10, 2022, 4:34PM
Benzinga - May 10, 2022, 9:21AM
Benzinga - May 10, 2022, 8:32AM
Benzinga - May 5, 2022, 3:28PM
Benzinga - May 5, 2022, 9:07AM
Benzinga - Apr 28, 2022, 7:35AM
Benzinga - Apr 13, 2022, 2:04PM
Benzinga - Apr 13, 2022, 7:40AM
load more
Sector: Health Care.Industry: Biotechnology
Turning Point Therapeutics Inc is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies. It owns a pipeline of next-generation tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The company's lead drug candidate, repotrectinib, is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-08
REV
Q1 2022Est.ActualSurprise
EPS-1.510-1.500 0.0100
REV429.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Turning Point Questions & Answers

Q
How do I buy Turning Point (TPTX) stock?
A

You can purchase shares of Turning Point (NASDAQ: TPTX) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Turning Point's (TPTX) competitors?
Q
What is the target price for Turning Point (TPTX) stock?
A

The latest price target for Turning Point (NASDAQ: TPTX) was reported by SVB Leerink on Monday, June 13, 2022. The analyst firm set a price target for 76.00 expecting TPTX to rise to within 12 months (a possible 1.18% upside). 16 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Turning Point (TPTX)?
A

The stock price for Turning Point (NASDAQ: TPTX) is $75.11 last updated July 1, 2022, 8:00 PM UTC.

Q
Does Turning Point (TPTX) pay a dividend?
A

There are no upcoming dividends for Turning Point.

Q
When is Turning Point (NASDAQ:TPTX) reporting earnings?
A

Turning Point’s Q2 earnings are confirmed for Monday, August 8, 2022.

Q
Is Turning Point (TPTX) going to split?
A

There is no upcoming split for Turning Point.

Q
What sector and industry does Turning Point (TPTX) operate in?
A

Turning Point is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.